Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, and 9 represent American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share ("ADS") of Quoin Pharmaceuticals, Ltd. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 4,804,161 ADS outstanding as of September 16, 2026, as disclosed in the Issuer's prospectus filed with the U.S. Securities and Exchange Commission (the "SEC") on September 25, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, and 9 represent American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share ("ADS") of Quoin Pharmaceuticals, Ltd. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 4,804,161 ADS outstanding as of September 16, 2026, as disclosed in the Issuer's prospectus filed with the U.S. Securities and Exchange Commission (the "SEC") on September 25, 2026.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:10/07/2026
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:10/07/2026

Comments accompanying signature:  A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on December 15, 2025 by the Reporting Persons with the SEC.
Exhibit Information

EXHIBIT 99 - JOINT FILING AGREEMENT


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 99 - JOINT FILING AGREEMENT